The failure of CAR-T cells in solid tumors is increasingly viewed as a metabolic disadvantage rather than an antigen-recognition problem. The metabolic hostility of the tumor microenvironment (TME), marked by glucose scarcity and toxic kynurenine accumulation, acts as a "metabolic wall" that induces rapid CAR-T exhaustion and failure in solid malignancies. Recent research confirms that overexpressing transporters like GLUT1/3 and enzymes like KYNU allows T cells to bypass these checkpoints. Notably, selecting the 4-1BB costimulatory domain shifts cell metabolism toward fatty acid oxidation, which is critical for maintaining a persistent memory phenotype in nutrient-deprived zones.

"By applying this knowledge, the industry may pivot towards 'context-aware' CAR-T engineering: utilizing synthetic sensors that trigger CAR-T survival responses only in response to TME-specific stressors. This dynamic regulation ensures that 'aggressive' CAR-T cells are localized to TMEs, improving overall systemic fitness and the safety of next-generation immunotherapies."

Nimit Mistry and others

Coultreon Biopharma is advancing COL-5671, an oral, once-daily inhibitor of salt-inducible kinase 3 (SIK3). This mechanism simultaneously suppresses pro-inflammatory cytokines (IL-23 and TNFα) while upregulating the immunoregulatory molecule IL-10, potentially offering more durable disease control than existing single-pathway biologics. Originally developed by Galapagos, COL-5671 has demonstrated preclinical efficacy across a spectrum of immune-mediated conditions. The USD $125M Series A funding, backed by Sofinnova, Novo Holdings, and Forbion, is earmarked to advance the candidate into Phase 2 trials for psoriasis and ulcerative colitis.

With clinical proof-of-concept data expected by 2027, Coultreon enters a crowded but high-value immunology market currently dominated by massive capital inflows and M&A. The focus on oral SIK3 inhibition positions the company to compete in the "precision immunology" space, aiming to provide a small-molecule alternative to traditional injectable therapies for chronic inflammatory diseases.

Herbert Smith Freehills Kramer has released its review of the EU pharma package, and how this affects pharma IP. The EU has finalized the most significant pharmaceutical overhaul in 20 years, replacing the rigid "8+2(+1)" exclusivity model with a modulated 8+1(+1)(+1) framework. While the 8-year regulatory data protection (RDP) baseline remains intact, the standard 2-year market protection has been halved to 1 year, with additional one-year extensions now contingent on meeting specific clinical or public health milestones.

Under the compromise texts published in March 2026, companies can "earn" back protection through three distinct pathways: addressing an unmet medical need, conducting comparative clinical trials in multiple Member States, or securing a new therapeutic indication with significant clinical benefit. Furthermore, a novel Transferable Exclusivity Voucher (TEV) for priority antimicrobials offers a 12-month RDP extension that can be applied to any centrally approved product in a firm's portfolio.

“The burden of proof has shifted to the innovator. Exclusivity is no longer an automatic right but a performance-based incentive designed to accelerate patient access and reward high-value innovation. R&D and launch strategies must align with these EU-specific criteria to avoid the "cliff" of earlier generic and biosimilar entry."

Nimit Mistry and others

For 20 years, Prix Galien USA has honored the breakthroughs shaping the future of healthcare and improving lives worldwide. Often regarded by the industry as the equivalent of the Nobel Prize of biopharmaceutical research, this is where innovation meets impact.

From groundbreaking therapies to life-saving technologies, this is more than an event, it’s a global movement advancing human health.

Follow The Galien Foundation on LinkedIn to stay updated on announcements, speakers, and innovations leading up to the event.

Eli Lilly has entered a strategic alliance with California-based startup Profluent to develop AI-designed recombinase editors. Valued at up to USD $2.25B in milestones plus royalties, the deal grants Lilly exclusive rights to commercialize custom enzymes capable of "gene writing", the precise insertion of entire functional genes into the human genome.

Profluent’s platform uses Large Language Models (LLMs) to move beyond the limitations of CRISPR/Cas9, which is primarily effective for small, localized edits (snips). By designing recombinases from scratch, the partnership aims to achieve kilobase-scale DNA insertion, allowing a single therapeutic to address diseases with high mutational heterogeneity. This "one-size-fits-all" approach for complex genetic disorders could replace the need for patient-specific variants.

Shares of Sun Pharma surged 12% over four trading days, significantly outperforming a declining Nifty 50, likely due to Sun Pharma's USD $11.75B all-cash acquisition of Organon. This move, executed at a 30.6% EBITDA margin, elevated Sun Pharma’s financial profile, with the company projecting the deal to be EPS accretive within the first 12 months.

The acquisition fundamentally reweights Sun’s portfolio, with the combined entity estimated to generate USD $12.4B in revenue, 27% of which will stem from innovative medicines. By absorbing Organon’s established women’s health and biosimilar franchises, Sun gains critical infrastructure, including six global manufacturing sites, and opens untapped geographical runways in China and South Korea.